Researchers at Case Western Reserve University discovered that the ratio between two proteins, human beta defensin 3 (hBD‐3) and human beta defensin 2 (hBD‐2), is an early biomarker of oral cancer in suspicious oral cavity lesions. The team validated a new non-invasive oral cancer test based on the ratio of…

A biosensor for oral cancer has been developed by researchers from the University of Florida and National Yang Ming Chiao Tung University in Taiwan. The device uses a rapid transistor-based system and is much faster and more convenient than current lab-based tests. Their study was published In Journal of Vacuum Science…

MDxHealth and QUT bluebox, the commercialization arm of the Queensland University of Technology (QUT), said today they will partner to develop a liquid biopsy epigenetic assay designed for early detection of oral cancer. The value of the collaboration was not disclosed. The test will evaluate abnormal DNA methylation changes, an…

The type of bacteria in a person’s mouth could help determine whether they are at high risk of head and neck cancer, according to research that adds to the reasons for keeping good oral health. The study, published in the journal JAMA Oncology, highlighted novel microbial risk factors that could…

Researchers at the German Cancer Research Center (DKFZ) have identified a membrane protein on the surface of cancer cells that supports and stabilizes an important factor involved in T-cell activation, thus potentially improving the anti-tumoral immune response. In recent years, Immune checkpoint inhibitors such as the anti-PD-L1 antibody nivolumab have…

Scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, have developed a first-of-its-kind, orally administered drug that can disrupt prostate cancer cell metabolism while simultaneously delivering the chemotherapy drug cisplatin directly into treatment-resistant prostate cancer cells. Cisplatin, a well established chemotherapy drug on the…

Direct acting oral anticoagulants (DOACs) are more cost-effective than low molecular weight heparin (LMWH) injections for the treatment of cancer-associated thrombosis, shows a new study published in the Annals of Internal Medicine. The findings “should help policymakers and clinicians with decision-making,” when considering the most suitable treatment for these patients,…

A new study in ovarian cancer found that using IgA-based antibodies produced by B cells may represent new immunotherapeutic agents for tumors resistant to conventional immune checkpoint blockade, which are currently focused on T cell-centric approaches. By design, immunotherapies are designed to boost the body’s T cells to recognize and…

  Researchers in the United States and China have recently released data from a study of the oral microbiome suggesting that the type and abundance of bacteria found in the mouth may be linked to lung cancer risk in nonsmokers. The study, which Albert Einstein College of Medicine assistant professor,…

Virginia Tech researchers have discovered that a species of bacteria commonly found in the mouth can migrate around the body via the blood and trigger existing colorectal cancer cells (CRC) to spread, or metastasize. Studies have previously linked Fusobacterium nucleatum with colorectal tumors, increased tumor microenvironment inflammation, and poor patient prognosis. The…

A research team at the Institute of Science in Tokyo, Japan, has developed a novel library of patient-derived tongue cancer organoids (TCOs) that could help drug developers understand the development of drug resistance in tongue cancer (TC). The organoids could suggest new drugs targeting autophagy and cholesterol synthesis pathways to…

A novel topical immunotherapy developed by researchers at Massachusetts General Hospital has shown promising results in preventing the development of squamous cell carcinoma (SCC), the second most common type of skin cancer. This therapy, which combines a vitamin D analog with chemotherapy, is the first to activate parts of the…

New data from the OlympiA clinical trial presented at the 2024 San Antonio Breast Cancer Symposium (SABCS) show that the PARP inhibitor olaparib (Lynparza) significantly improves survival in patients with high-risk, BRCA-positive, HER2-negative early breast cancer. The findings, after a median follow-up of 6.1 years, further support the drug’s use…

New research from the University of Pittsburgh and UPMC Hillman Cancer Center suggests that targeting the way immune cells absorb lactic acid could help reinvigorate exhausted T cells, enhancing their ability to fight cancer. The study, published in Nature Immunology, shows that blocking the protein responsible for transporting lactic acid…

A groundbreaking study from Harvard Medical School researchers should change long-held beliefs about the BRCA1 gene and its role in breast cancer. Researchers have discovered that even a single defective copy of the BRCA1 gene can make breast cells more susceptible to cancer, without the need for a second genetic…